RESUMO
The theme of health care and research in Italy is extremely large and complex. The two aspects are tackled in sequence though there are elements of combination related to the decree law 229 of 1999. Structural, organizational and financial elements of the two aspects, associated problems and possible proposed solutions are illustrated. Hopefully, in our country the approach to health care will change. Health care and research should be no longer considered from the viewpoint of expenditure but rather as an investment and quality should be perceived as gain rather than as cost.
Assuntos
Pesquisa Biomédica/tendências , Atenção à Saúde/tendências , Programas Nacionais de Saúde/tendências , Pesquisa Biomédica/legislação & jurisprudência , Atenção à Saúde/legislação & jurisprudência , Reforma dos Serviços de Saúde , Humanos , Itália , Programas Nacionais de Saúde/legislação & jurisprudênciaRESUMO
In 1986, we initiated a multicenter, randomized trial to compare induction chemotherapy with cisplatin and 5-fluorouracil followed by locoregional treatment (surgery and radiotherapy or radiotherapy alone) with locoregional treatment alone in patients with head and neck squamous cell carcinoma. Here we report the long-term results of the trial. A total of 237 patients with nonmetastatic stage III or IV head and neck carcinoma were randomly assigned to receive four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A) or locoregional treatment alone (group B). Among all patients, overall survival at 5 and 10 years was 23% (95% confidence interval [CI] = 15.3% to 30.9%) and 19% (95% CI = 11.6% to 26.4%), respectively, for those in group A and 16% (95% CI = 9.6% to 23.4%) and 9% (95% CI = 3.5% to 14.7%), respectively, for those in group B (P = .13). Among operable patients, we observed no difference between group A and group B in overall survival at 5 and 10 years (group A, 31% [95% CI = 14.9% to 47.3%] and 22.7% [95% CI = 7.1% to 38.3%], respectively; group B, 43.3% [95% CI = 25.6% to 61.0%] and 14.2% [95% CI = 0.1% to 28.3%], respectively; P = .73). Among inoperable patients, overall survival at 5 and 10 years was 21% (95% CI = 12.3% to 30.1%) and 16% (95% CI = 7.7% to 23.9%), respectively, for group A and 8% (95% CI = 1.5% to 12.3%) and 6% (95% CI = 0.1% to 9.1%), respectively, for group B (log-rank P = .04). Four cycles of neoadjuvant chemotherapy is a promising approach for treating patients with inoperable advanced head and neck cancer but not for treating patients with operable disease.